Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer — Physician’s First Watch
Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer
By Kelly Young
Biosimilar trastuzumab appears to have a similar effect on HER2-positive, early-stage breast cancer as standard trastuzumab (Herceptin), according to a study in Lancet Oncology that was presented at the American Society of Clinical Oncology's annual meeting.
Roughly 550 patients with HER2-positive, operable, early-stage breast cancer were randomized to receive either neoadjuvant trastuzumab or the trastuzumab biosimilar known as CT-P6 for 24 weeks. All patients also received neoadjuvant docetaxel, fluorouracil, epirubicin, and cyclophosphamide.
Rates of pathological complete response at the time of surgery were similar in the per-protocol analysis (47% for CT-P6 vs. 50% for reference trastuzumab). Adverse event rates were also similar.
The authors note that trastuzumab can cost up to $70,000, so a less expensive alternative would be welcome.